Gilead Sciences Target of Unusually Large Options Trading (GILD)
Shares of Gilead Sciences (NASDAQ:GILD) were the target of unusually large options trading on Friday. Stock investors purchased 95,735 call options on the stock, American Banking News.com reports. This is an increase of 217% compared to the typical daily volume of 30,213 call options.
In other Gilead Sciences news, Director Richard James Whitley sold 5,000 shares of Gilead Sciences stock on the open market in a transaction dated Friday, August 1st. The shares were sold at an average price of $91.00, for a total value of $455,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
GILD has been the subject of a number of recent research reports. Analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at RBC Capital initiated coverage on shares of Gilead Sciences in a research note on Friday. They set an “outperform” rating on the stock. Finally, analysts at FBR Capital Markets initiated coverage on shares of Gilead Sciences in a research note on Thursday. They set an “outperform” rating and a $125.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and twenty-one have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $105.05.
Shares of Gilead Sciences (NASDAQ:GILD) traded up 3.25% during mid-day trading on Friday, hitting $99.49. The stock had a trading volume of 19,678,324 shares. Gilead Sciences has a 52-week low of $56.25 and a 52-week high of $96.37. The stock has a 50-day moving average of $89.64 and a 200-day moving average of $81.09. The company has a market cap of $150.4 billion and a P/E ratio of 21.83.
Gilead Sciences (NASDAQ:GILD) last released its earnings data on Wednesday, July 23rd. The company reported $2.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was up 136.1% on a year-over-year basis. Analysts expect that Gilead Sciences will post $8.02 EPS for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.